Pure Global
NCT05786534

Therapeutic Effect of Green Seaweed Against Metabloc Syndrome

Therapeutic Potential of Green Seaweed, Ulva Lactuca, Against Metabolic Syndrome
University of Veterinary and Animal Sciences, Lahore - Pakistan·ClinicalTrials.gov·dietary supplementEnrolling by invitation
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Metabolic Syndrome
Drug/Device/Intervention
Green Seaweed
Study type
Interventional
Intervention type
dietary supplement
Sponsor & location
Primary sponsor
University of Veterinary and Animal Sciences, Lahore - Pakistan
Location
Gujrānwāla, Pakistan
Timeline & enrollment
Phase
N/A
Start date
Dec 27, 2022
End date
Aug 24, 2023
Enrollment
40 participants
Primary outcome

Blood pressure will be assessed before and after the trial,Lipid profile will be assessed before and after the trial,Fasting glucose level will be assessed before and after the trial,Weight will be measured before and after the trial

Summary

Metabolic syndrome is a major concern worldwide and in Pakistan as well. Metabolic syndrome
 is a pathologic condition which includes abdominal obesity, insulin resistance, hypertension
 and hyperlipidemia. Seafood consumption has been linked to reduced risk of many health
 conditions including altered blood profile. Green seaweed is known to have a potential in
 optimizing the blood profile and so, it is helpful in reducing the risk of metabolic syndrome
 by playing a role in preventing obesity, hyperglycemia, high blood pressure and altered lipid
 profile. Green seaweed (Ulva Lactuca) powder will prove to have therapeutic potential against
 obesity, hypertension, glucose intolerance and dyslipidemia.

ICD-10 classifications
Metabolic disordersMetabolic disorder, unspecifiedOther metabolic disordersOther specified metabolic disordersNutritional and metabolic disorders in diseases classified elsewhere
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05786534
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05786534 through Pure Global AI's free database. This phase not specified trial is sponsored by University of Veterinary and Animal Sciences, Lahore - Pakistan and is currently Enrolling by invitation. The study focuses on Metabolic Syndrome. Target enrollment is 40 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.